Progression-free survival significantly lower with fixed-duration acalabrutinib-venetoclax with or without obinutuzumab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback